Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2016 · 10-K
Revenue$68.00K$68.00K−13.9% vs Q4 2015 Net Income-$8.55M-$8.55MderivedN/M vs Q4 2015 EPS Diluted-$0.34-$0.34N/M vs Q4 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
-$9,782,231
N/M
Operating Cash Flowderived-$9,004,857N/M Free Cash Flowderived-$9,030,559N/M Margins · derivedOperating margin-14385.6%−5038.6 pt vs Q4 2015
Net margin-12570.1%−3227.2 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 15, 2017 · 74 d after period end